Manhattan Scientifics, Inc. (OTCPK:MHTX) will seek acquisition. After successfully spinning-out and taking public its cancer diagnostic technology (IBX) and exclusively licensing its other metals technology, Manhattan Scientifics will enter its third phase of activity - to acquire a substantial technology company and to uplist MHTX to a national securities exchange such as the Nasdaq Capital Market. We remain optimistic about prospects for commercialization of our two nanotechnology developments and we are actively engaged in early discussions with prospective companies that wish to go public via the process of merging with us.